Real‐world use of idarucizumab for dabigatran reversal in three cases of serious bleeding

Bleeding is a rare complication of direct oral anticoagulant potentially associated with high mortality rates. Biological monitoring is necessary for more than 24 h after idarucizumab antidote therapy in case of bleeding with dabigatran therapy.

Detalles Bibliográficos
Autores principales: Gendron, Nicolas, Feral‐Pierssens, Anne Laure, Jurcisin, Igor, de Raucourt, Emmanuelle, Bouton, Valerie, Fischer, Anne Marie, Lorenceau‐Savale, Camille, Lillo‐Le Louët, Agnès, Smadja, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331231/
https://www.ncbi.nlm.nih.gov/pubmed/28265404
http://dx.doi.org/10.1002/ccr3.839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331231/
https://www.ncbi.nlm.nih.gov/pubmed/28265404
http://dx.doi.org/10.1002/ccr3.839

Ejemplares similares